Artemis Medicare Services Limited has informed the Exchange regarding Change in Director(s) of the company.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services Limited held its Board Meeting on May 8, 2026, approving audited financial results for Q4 and FY26 ended March 31, 2026. Standalone revenue grew to ₹1,06,049 Lacs from ₹91,326 Lacs year-on-year, with net profit at ₹10,344 Lacs versus ₹8,346 Lacs previously. The Board recommended a final dividend of ₹0.45 per equity share (45%) for FY26, subject to shareholder approval. Two new Independent Directors were appointed: Mr. Tapan Mitra (Additional Director effective May 8, 2026) and Dr. Girdhar J. Gyani (appointment proposed from August 1, 2026). Statutory auditors T R Chadha & Co LLP were re-appointed for a second 5-year term. The company also extended the utilization period for unutilized preferential issue funds by 18 months.
Strong operational performance with ~24% revenue growth and ~24% increase in net profit is positive for shareholders. The dividend recommendation provides immediate cash returns. New independent director appointments strengthen board governance.